Nanoparticle therapy boosts antitumor immunity via immunogenic cell death, affecting macrophage types and reactive oxygen species levels.
Damage-associated molecular patterns (DAMPs) are released by cells through immunogenic cell death (ICD), reshaping the tumor microenvironment and demonstrating significant potential in cancer immunotherapy. We report a type of nanoparticle (FeS-IMQ-MnO₂@HA) in which Hyaluronic acid (HA) targets the CD44 receptor of tumor cells. Under low-temperature photothermal therapy (LTPTT), FeS within the nanoparticles generates Fe²⁺ through chemodynamic therapy (CDT), thereby producing reactive oxygen species (ROS) that mediate ICD and activate immune responses, enhancing the treatment of solid tumors. MnO₂ nanoparticles are used to lower glutathione (GSH) levels at tumor sites, increasing the anti-tumor activity of ROS. Concurrently, hydrogen sulfide (H₂S) modulates the metabolic environment of tumor cells, inducing acidosis and enhancing lactate production, which increases Ca²⁺ influx, leading to mitochondrial damage and the release of oxidized mitochondrial DNA. This promotes the transformation of tumor-associated macrophages to the M1 phenotype, enhancing the effectiveness of tumor immunotherapy. This strategy provides a new perspective by modulating the tumor microenvironment and activating immune responses, showcasing the potential of ICD in improving tumor treatment responses.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: